NDAINTRAVENOUSEMULSION
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARUBI (rolapitant hydrochloride) is an intravenous NK1 receptor antagonist indicated for prevention of chemotherapy-induced nausea and vomiting (CINV). It works by blocking neurokinin-1 receptors in the chemoreceptor trigger zone and vomiting center. The drug is administered as an IV emulsion prior to chemotherapy.
Peak5.8 years to LOE
Product is in peak lifecycle stage with stable commercial performance; team size and recruitment activity currently limited.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VARUBI positions you in a stable, mature oncology supportive care franchise within TerSera Therapeutics. Career growth depends on defensive commercial excellence and life-cycle management rather than launch momentum or expansion trials.
Brand ManagerRegional Sales Manager
Worked on VARUBI at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.